Oncimmune has announced an autoantibody profiling contract with the prestigious DanaFarber Cancer Institute. The contract opens up ImmunoINSIGHTS autoantibody profiling service to a number of Dana-Farber led oncology studies. We estimate the contract win to have minimal initial financial value, but importantly it brings influence and provides a framework for future use amongst pharmaceutical sponsors. Consequently, we make no changes to our estimates (projected 66% CAGR FY’21-23 in ImmunoINSIGHT ....
23 Jul 2021
ImmunoINSIGHTS win; COVID yesterday, cancer today
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
ImmunoINSIGHTS win; COVID yesterday, cancer today
Oncimmune Holdings Plc (ONC:LON) | 27.6 -0.4 (-5.2%) | Mkt Cap: 20.5m
- Published:
23 Jul 2021 -
Author:
Edward Thomason -
Pages:
3
Oncimmune has announced an autoantibody profiling contract with the prestigious DanaFarber Cancer Institute. The contract opens up ImmunoINSIGHTS autoantibody profiling service to a number of Dana-Farber led oncology studies. We estimate the contract win to have minimal initial financial value, but importantly it brings influence and provides a framework for future use amongst pharmaceutical sponsors. Consequently, we make no changes to our estimates (projected 66% CAGR FY’21-23 in ImmunoINSIGHT ....